Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference102 articles.
1. Metastatic breast cancer: preliminary results with oral hormonal therapy;Allegra;Semin. Oncol.,1985
2. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study;Bachelot;J. Clin. Oncol.,2012
3. Phase II randomized study of neoadjuvanteverolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer;Baselga;J. Clin. Oncol.,2009
4. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N. Engl. J. Med.,2012
5. Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer;Bedard;Breast Cancer Res. Treat.,2008
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Loss of Hormone Receptor Expression after Exposure to Fluid Shear Stress in Breast Cancer Cell Lines;International Journal of Molecular Sciences;2024-06-28
2. Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer;Heliyon;2023-08
3. Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study;Frontiers in Oncology;2023-01-12
4. MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer;Clinical Cancer Research;2021-08-10
5. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis;Expert Opinion on Drug Safety;2021-08-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3